SARM
AC-262536
SaveA partial androgen receptor agonist with lower potency than LGD-4033, studied preclinically for tissue-selective anabolic effects with reduced prostate stimulation.
Quick verdict
Very early-stage compound with only animal data. Not well characterized in humans.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Rodent studies show roughly 66% of the anabolic activity of testosterone with about 27% of its androgenic activity. No published human trials.
Benefits
- Preclinical tissue selectivity in rodent models
- Lower androgenic activity relative to anabolic effect in animals
Dosage notes
No human-validated dosing exists.
Side effects
- Unknown in humans
- Potential hormonal suppression
Who should be cautious
Not approved for human use. No human safety or pharmacokinetic data. Gray-market sourcing carries purity risk.
What this page cannot tell you
All efficacy data comes from animal models. Translating partial-agonist profiles to humans is unreliable.
Leaderboard scores
- Muscle30
- Recovery20
Write a review
Sign in to write a review.